Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. Show more
Location: 1901 West 47th Place, Kansas City, KS, 66205, United States | Website: https://www.cingulate.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
21.95M
52 Wk Range
$1.80 - $20.83
Previous Close
$4.81
Open
$4.87
Volume
154,634
Day Range
$4.77 - $5.25
Enterprise Value
12.84M
Cash
9.519M
Avg Qtr Burn
-3.578M
Insider Ownership
2.40%
Institutional Own.
3.22%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
CTx-1301 (dexmethylphenidate) Details Attention deficit hyperactivity disorder | NDA Submission | |
CTx-1302 (dextroamphetamine) Details Attention deficit hyperactivity disorder | Phase 1/2 Initiation | |
CTx-2103 (buspirone) Details Anxiety Disorders | IND Submission |